Related Experiment Video
Updated: Mar 6, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Differences in IP‑10, TLR4 and IRF5/3 between SVR and non‑SVR HCV‑1 patients treated with PEG‑IFN and ribavirin
Min Zhang1, Yongfang Jiang1, Xinqiang Xiao1
1Institute of Hepatology and Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China.
Abstract:
The present study aimed to investigate alterations in Toll‑like receptor 4 (TLR4), interferon regulatory factor 5 (IRF5) and interferon‑γ‑inducible protein‑10 (IP‑10), and evaluate whether these factors may be associated with a sustained virological response (SVR) among patients with hepatitis C virus genotype‑1 (HCV‑1) who were treated with peginterferon plus ribavirin (PEG‑IFN‑RBV). A total of 31 Chinese patients infected with HCV‑1 were enrolled in the present study and 25 patients obtained SVR. The expression levels of IP‑10 declined significantly during PEG‑IFN‑RBV therapy at the 24 and 48 week time‑points, compared with the baseline (P<0.005, 0.001 and 0.001, respectively). In addition, it was observed that IRF5 mRNA expression and the number of TLR4+ peripheral blood mononuclear cells exhibited similar correlations with IP‑10 concentration (R2=0.0726, P=0.001, R2=0.1634, P<0.0001, respectively) in the SVR group patients; however, these correlations were not observed to be present in the non‑SVR group patients. In conclusion, the results of the present study suggest that marked alterations in IP‑10, TLR4 and IRF5 expression may serve as indicators for the development of SVR in patients with HCV‑1 treated with PEG‑IFN‑RBV.
Insights
Investigating Toll-like receptor 4 (TLR4), interferon regulatory factor 5 (IRF5), and interferon-γ-inducible protein-10 (IP-10) revealed their association with sustained virological response (SVR) in hepatitis C virus genotype-1 (HCV-1) patients. These biomarkers indicate treatment success with peginterferon plus ribavirin (PEG-IFN-RBV).
Area of Science:
- Hepatology and Virology
- Immunology and Molecular Biology
Background:
- Hepatitis C virus genotype-1 (HCV-1) infection poses a significant global health challenge.
- Peginterferon plus ribavirin (PEG-IFN-RBV) is a standard treatment, but predicting sustained virological response (SVR) remains crucial.
- Toll-like receptor 4 (TLR4), interferon regulatory factor 5 (IRF5), and interferon-γ-inducible protein-10 (IP-10) are key immune modulators.
Purpose of the Study:
- To investigate alterations in TLR4, IRF5, and IP-10 during PEG-IFN-RBV therapy for HCV-1.
- To evaluate the association of these factors with the achievement of SVR in treated patients.
Main Methods:
- Analysis of 31 Chinese patients with HCV-1 treated with PEG-IFN-RBV.
- Measurement of IP-10 expression levels at baseline, 24, and 48 weeks.
- Assessment of IRF5 mRNA expression and TLR4+ peripheral blood mononuclear cells in relation to IP-10 concentration.
Main Results:
- IP-10 expression significantly declined during PEG-IFN-RBV therapy (P<0.005).
- IRF5 mRNA and TLR4+ cell counts correlated with IP-10 levels in patients achieving SVR (R²=0.0726, P=0.001 and R²=0.1634, P<0.0001, respectively).
- These correlations were not observed in patients who did not achieve SVR.
Conclusions:
- Significant alterations in IP-10, TLR4, and IRF5 expression are associated with treatment outcomes in HCV-1.
- These biomarkers may serve as predictive indicators for developing SVR in HCV-1 patients undergoing PEG-IFN-RBV therapy.
- Further research can explore these markers for personalized treatment strategies.
